The Beauty Health Company (NASDAQ:SKIN) Receives Consensus Rating of “Hold” from Analysts

The Beauty Health Company (NASDAQ:SKIN) has received a consensus rating of “Hold” from the eight research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $2.02.

A number of equities analysts have recently issued reports on SKIN shares. TD Cowen reduced their target price on shares of Beauty Health from $1.65 to $1.50 and set a “hold” rating on the stock in a research report on Monday, March 16th. Benchmark reissued a “hold” rating on shares of Beauty Health in a report on Friday, March 13th. Canaccord Genuity Group reduced their price objective on Beauty Health from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Zacks Research upgraded Beauty Health from a “strong sell” rating to a “hold” rating in a research report on Monday, March 16th. Finally, Roth Mkm reissued a “buy” rating and issued a $2.00 target price (down from $2.50) on shares of Beauty Health in a research note on Wednesday, May 20th.

Beauty Health Stock Performance

Beauty Health stock opened at $0.77 on Friday. The stock has a 50-day simple moving average of $0.85 and a 200 day simple moving average of $1.16. The stock has a market capitalization of $100.28 million, a price-to-earnings ratio of -4.55 and a beta of 1.12. The company has a quick ratio of 1.48, a current ratio of 1.79 and a debt-to-equity ratio of 4.37. Beauty Health has a 12-month low of $0.55 and a 12-month high of $2.69.

Beauty Health (NASDAQ:SKIN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The firm had revenue of $64.91 million for the quarter, compared to analyst estimates of $66.28 million. Beauty Health had a negative net margin of 2.03% and a negative return on equity of 9.38%. On average, research analysts anticipate that Beauty Health will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Beauty Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new stake in Beauty Health in the third quarter worth about $26,000. Franklin Resources Inc. acquired a new position in Beauty Health during the 3rd quarter valued at about $31,000. Zacks Investment Management bought a new position in shares of Beauty Health in the 3rd quarter valued at about $35,000. Ameriprise Financial Inc. bought a new position in shares of Beauty Health in the 3rd quarter valued at about $38,000. Finally, Atom Investors LP acquired a new stake in shares of Beauty Health during the 4th quarter worth approximately $29,000. 93.26% of the stock is currently owned by institutional investors and hedge funds.

Beauty Health Company Profile

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.